Costs and Expenses of VERTEX PHARMACEUTICALS INC / MA from 31 Mar 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly and annual Costs and Expenses in USD history and change rate from 31 Mar 2010 to 31 Dec 2025.
  • VERTEX PHARMACEUTICALS INC / MA Costs and Expenses for the quarter ending 31 Dec 2025 was $1,984,100,000, a 5.2% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA Costs and Expenses for the twelve months ending 31 Dec 2025 was $7,828,000,000, a 30% decline year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA annual Costs and Expenses for 2025 was $7,828,000,000, a 30% decline from 2024.
  • VERTEX PHARMACEUTICALS INC / MA annual Costs and Expenses for 2024 was $11,253,000,000, a 86% increase from 2023.
  • VERTEX PHARMACEUTICALS INC / MA annual Costs and Expenses for 2023 was $6,037,200,000, a 31% increase from 2022.
Source SEC data
View on sec.gov
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Change (%)
Costs and Expenses, Annual (USD)
Costs and Expenses, YoY Annual Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Costs and Expenses (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $7,828,000,000 $1,984,100,000 +$98,100,000 +5.2% 01 Oct 2025 31 Dec 2025 10-K 13 Feb 2026 2025 FY
Q3 2025 $7,729,900,000 $1,890,200,000 +$234,600,000 +14% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $7,495,300,000 $1,813,600,000 -$4,346,700,000 -71% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $11,842,000,000 $2,140,100,000 +$589,000,000 +38% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $11,253,000,000 $1,886,000,000 +$356,800,000 +23% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
Q3 2024 $10,896,200,000 $1,655,600,000 +$210,200,000 +15% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $10,686,000,000 $6,160,300,000 +$4,693,500,000 +320% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $5,992,500,000 $1,551,100,000 -$44,700,000 -2.8% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $6,037,200,000 $1,529,200,000 +$260,000,000 +20% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2026 2025 FY
Q3 2023 $5,777,200,000 $1,445,400,000 +$237,800,000 +20% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $5,539,400,000 $1,466,800,000 +$376,900,000 +35% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q2
Q1 2023 $5,162,500,000 $1,595,800,000 +$539,200,000 +51% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $4,623,300,000 $1,269,200,000 +$74,300,000 +6.2% 01 Oct 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
Q3 2022 $4,549,000,000 $1,207,600,000 +$278,000,000 +30% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $4,271,000,000 $1,089,900,000 -$741,400,000 -40% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $5,012,400,000 $1,056,600,000 +$220,100,000 +26% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q4 2021 $4,792,300,000 $1,194,900,000 +$312,872,000 +35% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $4,479,428,000 $929,600,000 +$63,570,000 +7.3% 01 Jul 2021 30 Sep 2021 10-Q 28 Oct 2022 2022 Q3
Q2 2021 $4,415,858,000 $1,831,300,000 +$1,024,848,000 +127% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2022 Q2
Q1 2021 $3,391,010,000 $836,500,000 +$41,617,000 +5.2% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $3,349,393,000 $882,028,000 +$20,228,000 +2.3% 01 Oct 2020 31 Dec 2020 10-K 11 Feb 2021 2020 FY
Q3 2020 $3,329,165,000 $866,030,000 +$15,535,000 +1.8% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $3,313,630,000 $806,452,000 +$135,119,000 +20% 01 Apr 2020 30 Jun 2020 10-Q 30 Jul 2021 2021 Q2
Q1 2020 $3,178,511,000 $794,883,000 +$213,256,000 +37% 01 Jan 2020 31 Mar 2020 10-Q 30 Apr 2021 2021 Q1
Q4 2019 $2,965,255,000 $861,800,000 +$119,416,000 +16% 01 Oct 2019 31 Dec 2019 10-K 11 Feb 2021 2020 FY
Q3 2019 $2,845,839,000 $850,495,000 +$271,609,000 +47% 01 Jul 2019 30 Sep 2019 10-K 11 Feb 2021 2020 FY
Q2 2019 $2,574,230,000 $671,333,000 +$92,054,000 +16% 01 Apr 2019 30 Jun 2019 10-K 11 Feb 2021 2020 FY
Q1 2019 $2,482,176,000 $581,627,000 +$69,729,000 +14% 01 Jan 2019 31 Mar 2019 10-K 11 Feb 2021 2020 FY
Q4 2018 $2,412,447,000 $742,384,000 +$216,487,000 +41% 01 Oct 2018 31 Dec 2018 10-K 13 Feb 2020 2019 FY
Q3 2018 $2,195,960,000 $578,886,000 -$325,322,000 -36% 01 Jul 2018 30 Sep 2018 10-K 13 Feb 2020 2019 FY
Q2 2018 $2,521,282,000 $579,279,000 +$87,851,000 +18% 01 Apr 2018 30 Jun 2018 10-K 13 Feb 2020 2019 FY
Q1 2018 $2,433,431,000 $511,898,000 +$68,022,000 +15% 01 Jan 2018 31 Mar 2018 10-K 13 Feb 2020 2019 FY
Q4 2017 $2,365,409,000 $525,897,000 +$106,831,000 +25% 01 Oct 2017 31 Dec 2017 10-K 13 Feb 2019 2018 FY
Q3 2017 $2,258,578,000 $904,208,000 +$471,698,000 +109% 01 Jul 2017 30 Sep 2017 10-K 13 Feb 2019 2018 FY
Q2 2017 $1,786,880,000 $491,428,000 +$63,173,000 +15% 01 Apr 2017 30 Jun 2017 10-K 13 Feb 2019 2018 FY
Q1 2017 $1,723,707,000 $443,876,000 +$31,466,000 +7.6% 01 Jan 2017 31 Mar 2017 10-K 13 Feb 2019 2018 FY
Q4 2016 $1,692,241,000 $419,066,000 -$52,573,000 -11% 01 Oct 2016 31 Dec 2016 10-K 15 Feb 2018 2017 FY
Q3 2016 $1,744,814,000 $432,510,000 +$52,668,000 +14% 01 Jul 2016 30 Sep 2016 10-K 15 Feb 2018 2017 FY
Q2 2016 $1,692,146,000 $428,255,000 +$91,015,000 +27% 01 Apr 2016 30 Jun 2016 10-K 15 Feb 2018 2017 FY
Q1 2016 $1,601,131,000 $412,410,000 +$101,916,000 +33% 01 Jan 2016 31 Mar 2016 10-K 15 Feb 2018 2017 FY
Q4 2015 $1,499,215,000 $471,639,000 +$173,458,000 +58% 01 Oct 2015 31 Dec 2015 10-K 23 Feb 2017 2016 FY
Q3 2015 $1,325,757,000 $379,842,000 +$58,652,000 +18% 01 Jul 2015 30 Sep 2015 10-K 23 Feb 2017 2016 FY
Q2 2015 $1,267,105,000 $337,240,000 +$18,277,000 +5.7% 01 Apr 2015 30 Jun 2015 10-K 23 Feb 2017 2016 FY
Q1 2015 $1,248,828,000 $310,494,000 -$23,999,000 -7.2% 01 Jan 2015 31 Mar 2015 10-K 23 Feb 2017 2016 FY
Q4 2014 $1,272,827,000 $298,181,000 -$63,257,000 -18% 01 Oct 2014 31 Dec 2014 10-K 16 Feb 2016 2015 FY
Q3 2014 $1,336,084,000 $321,190,000 -$24,066,000 -7% 01 Jul 2014 30 Sep 2014 10-K 16 Feb 2016 2015 FY
Q2 2014 $1,360,150,000 $318,963,000 -$38,819,000 -11% 01 Apr 2014 30 Jun 2014 10-K 16 Feb 2016 2015 FY
Q1 2014 $1,398,969,000 $334,493,000 -$423,014,000 -56% 01 Jan 2014 31 Mar 2014 10-K 16 Feb 2016 2015 FY
Q4 2013 $1,821,983,000 $361,438,000 -$50,032,000 -12% 01 Oct 2013 31 Dec 2013 10-K 13 Feb 2015 2014 FY
Q3 2013 $1,872,015,000 $345,256,000 +$8,179,000 +2.4% 01 Jul 2013 30 Sep 2013 10-K 13 Feb 2015 2014 FY
Q2 2013 $1,863,836,000 $357,782,000 -$71,293,000 -17% 01 Apr 2013 30 Jun 2013 10-K 13 Feb 2015 2014 FY
Q1 2013 $1,935,129,000 $757,507,000 +$410,419,000 +118% 01 Jan 2013 31 Mar 2013 10-K 13 Feb 2015 2014 FY
Q4 2012 $1,524,710,000 $411,470,000 +$72,032,000 +21% 01 Oct 2012 31 Dec 2012 10-K 11 Feb 2014 2013 FY
Q3 2012 $1,452,678,000 $337,077,000 -$106,416,000 -24% 01 Jul 2012 30 Sep 2012 10-K 11 Feb 2014 2013 FY
Q2 2012 $1,559,094,000 $429,075,000 +$148,761,000 +53% 01 Apr 2012 30 Jun 2012 10-K 11 Feb 2014 2013 FY
Q1 2012 $1,410,333,000 $347,088,000 +$113,527,000 +49% 01 Jan 2012 31 Mar 2012 10-K 11 Feb 2014 2013 FY
Q4 2011 $1,296,806,000 $339,438,000 +$107,280,000 +46% 01 Oct 2011 31 Dec 2011 10-K 01 Mar 2013 2012 FY
Q3 2011 $1,189,526,000 $443,493,000 +$220,110,000 +99% 01 Jul 2011 30 Sep 2011 10-K 01 Mar 2013 2012 FY
Q2 2011 $969,416,000 $280,314,000 +$79,119,000 +39% 01 Apr 2011 30 Jun 2011 10-K 01 Mar 2013 2012 FY
Q1 2011 $890,297,000 $233,561,000 +$50,850,000 +28% 01 Jan 2011 31 Mar 2011 10-K 01 Mar 2013 2012 FY
Q4 2010 $839,447,000 $232,158,000 01 Oct 2010 31 Dec 2010 10-K 22 Feb 2012 2011 FY
Q3 2010 $223,383,000 01 Jul 2010 30 Sep 2010 10-K 22 Feb 2012 2011 FY
Q2 2010 $201,195,000 01 Apr 2010 30 Jun 2010 10-K 22 Feb 2012 2011 FY
Q1 2010 $182,711,000 01 Jan 2010 31 Mar 2010 10-K 22 Feb 2012 2011 FY

VERTEX PHARMACEUTICALS INC / MA Annual Costs and Expenses (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $7,828,000,000 -$3,425,000,000 -30% 01 Jan 2025 31 Dec 2025 10-K 13 Feb 2026 2025 FY
2024 $11,253,000,000 +$5,215,800,000 +86% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
2023 $6,037,200,000 +$1,413,900,000 +31% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2026 2025 FY
2022 $4,623,300,000 -$169,000,000 -3.5% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $4,792,300,000 +$1,442,900,000 +43% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $3,349,400,000 +$384,100,000 +13% 01 Jan 2020 31 Dec 2020 10-K 10 Feb 2023 2022 FY
2019 $2,965,300,000 +$552,853,000 +23% 01 Jan 2019 31 Dec 2019 10-K 09 Feb 2022 2021 FY
2018 $2,412,447,000 +$47,038,000 +2% 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $2,365,409,000 +$673,168,000 +40% 01 Jan 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
2016 $1,692,241,000 +$193,026,000 +13% 01 Jan 2016 31 Dec 2016 10-K 13 Feb 2019 2018 FY
2015 $1,499,215,000 +$226,388,000 +18% 01 Jan 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
2014 $1,272,827,000 -$549,156,000 -30% 01 Jan 2014 31 Dec 2014 10-K 23 Feb 2017 2016 FY
2013 $1,821,983,000 +$341,668,000 +23% 01 Jan 2013 31 Dec 2013 10-K 16 Feb 2016 2015 FY
2012 $1,480,315,000 +$183,509,000 +14% 01 Jan 2012 31 Dec 2012 10-K 13 Feb 2015 2014 FY
2011 $1,296,806,000 +$457,359,000 +54% 01 Jan 2011 31 Dec 2011 10-K 11 Feb 2014 2013 FY
2010 $839,447,000 01 Jan 2010 31 Dec 2010 10-K 01 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.